OxOnc to Partner With Pfizer Inc. on China Cancer Drug Trial

by Richard Daverman, PhD

February 11, 2013 -- OxOnc Development LLP, an oncology company headquartered in Princeton, NJ, has signed a co-development agreement with Pfizer to conduct a Phase III clinical trial of a Pfizer cancer drug in China, Taiwan, Japan and South Korea. The drug, crizotinib (marketed as Xalkori®), will be tested in patients with advanced non-small cell lung cancer who have a ROS1 (c-ros) gene rearrangement (ROS1-positive). The drug is already approved in the US, Europe, China and Japan for NSCLC patients with the ALK genetic variation. More details....

Stock Symbol: (NYSE: PFE)